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Abstract
Aims/hypothesis The bone-related peptide osteoprotegerin
is produced by vascular cells and is involved in the process
of vascular calcification. The aim of this study was to
investigate the predictive value of plasma levels of
osteoprotegerin in relation to mortality, cardiovascular
events and deterioration in kidney function in patients with
type 1 diabetes.
Methods This prospective observational follow-up study
included 397 type 1 diabetic patients with overt diabetic
nephropathy (243 men; age [mean±SD] 42.1±10.6 years,
duration of diabetes 28.3±9.9 years, GFR 67±28 ml min−1
1.73 m2) and a group of 176 patients with longstanding
type 1 diabetes and persistent normoalbuminuria (105 men;
age 42.6±9.7 years, duration of diabetes 27.6±8.3 years).
Results The median (range) follow-up period was 11.3
(0.0–12.9) years. Among patients with diabetic nephropa-
thy, individuals with high osteoprotegerin levels (fourth
quartile) had significantly higher all-cause mortality than
patients with low levels (first quartile) (covariate-adjusted
hazard ratio [HR] 3.00 [1.24–7.27]). High osteoprotegerin
levels also predicted cardiovascular mortality (covariate-
adjusted HR 4.88 [1.57–15.14]). Furthermore, patients with
high osteoprotegerin levels had significantly higher risk of
progression to end-stage renal disease than patients with
low levels (covariate-adjusted HR 4.32 [1.45–12.87]). In
addition, patients with high levels of plasma osteoprote-
gerin had an elevated rate of decline in GFR.
Conclusions/interpretation High levels of osteoprotegerin
predict all-cause and cardiovascular mortality in patients
with diabetic nephropathy. Furthermore, high levels of
osteoprotegerin predict deterioration of kidney function
towards end-stage renal disease.
Keywords Cardiovascular events . Diabetes . Diabetic
nephropathy . End-stage renal disease . Glomerular filtration
rate . Mortality . Osteoprotegerin
Abbreviations
ESRD end-stage renal disease
HR hazard ratio
UAER urinary albumin excretion rate
NT-proBNP N-terminal prohormone brain
natriuretic peptide
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Introduction
Despite improvements achieved during recent years in the
treatment of type 1 diabetic patients, the long-term
prognosis for these patients is still considerably worse than
among individuals without diabetes. This unfortunate fact is
founded on a high incidence of cardiovascular disease and
end-stage renal disease (ESRD), due to the development of
diabetic angiopathy.
Osteoprotegerin is present in bone and has moreover been
found to play an important role in the vasculature. The
molecule was discovered in 1997, where it was shown to
function as a strong inhibitor of osteoclast formation in bone
[1, 2]. The peptide is a soluble TNF-receptor-like molecule
without a membrane-spanning part [3]. It has been proposed
that osteoprotegerin may be involved in the development of
calcifications in the arterial wall, where the molecule is
present in concentrations comparable with those in bone [4].
Supporting this idea, studies have shown that expression of
the gene encoding osteoprotegerin and production of the
protein are altered in arterial areas with calcification [5].
However, the exact functions of osteoprotegerin in relation
to vascular calcifications and other arterial functions are not
yet well defined [6–9]. Interestingly, we have previously
observed that osteoprotegerin accumulates in human aortic
tissue from patients with type 1 and type 2 diabetes, a
finding that has very recently been confirmed in studies of
experimental models of diabetic arteriopathy [10, 11].
Osteoprotegerin can be detected in plasma, but at present
there is no information about the predominant source of
circulating osteoprotegerin and nothing is known about its
elimination from the blood. Plasma levels are increased in
patients with diabetes [12, 13] as well as in non-diabetic
individuals with coronary artery disease [12, 14, 15]. Of
particular interest, the plasma osteoprotegerin concentration
correlates to the degree of arterial calcification [16, 17], a
phenomenon often observed in patients with diabetes [16,
17]. Furthermore, a relationship between increased plasma
osteoprotegerin concentration and micro- and macrovascu-
lar parameters has been observed in patients with type 1
[18] and type 2 diabetes [13]. In addition, a few recent
studies indicate that plasma osteoprotegerin may be a
strong and independent predictor of cardiovascular events
in some populations. This has been shown to be the case in
patients with type 2 diabetes [19], as well as in non-diabetic
patients after kidney transplantation [20] and after myocar-
dial infarction [21].
In this paper, we extend previously observed correla-
tions between plasma osteoprotegerin and cardiovascular
risk factors in type 1 diabetic individuals with data on the
capacity of plasma osteoprotegerin to predict death, cardio-
vascular events and ESRD through more than 11 years of
follow-up.
Methods
Patients During 1993, 198 type 1 diabetic patients with
diabetic nephropathy, whose GFR had been measured
during the same year, were recruited from the outpatient
clinic at Steno Diabetes Center for a case–control study.
Simultaneously, a group of 192 patients with long-lasting
type 1 diabetes and persistent normoalbuminuria were
recruited as controls. Since then, all type 1 diabetic patients
newly referred for measurement of kidney function have
been invited to participate in an ongoing study of the
genetics of diabetic nephropathy, and thus the original
cohort of type 1 diabetic patients with diabetic nephropathy
was expanded to 408 patients.
Plasma osteoprotegerin levels were determined and
follow-up data were available for 397 (97%) patients with
diabetic nephropathy and 176 (92%) controls.
Type 1 diabetes was considered present if the age at
onset of diabetes was ≤35 years and time to definite insulin
therapy was ≤1 year. Established diabetic nephropathy was
defined by persistent albuminuria (>300 mg/24 h) in two
out of three consecutive measurements in sterile urine
samples, the presence of retinopathy and the absence of
other kidney or urinary tract diseases [22]. In patients
without retinopathy (n=6) the diagnosis of diabetic glo-
merulopathy was verified by a kidney biopsy. Controls
were patients with persistent normoalbuminuria (<30 mg/
24 h) after at least 15 years of type 1 diabetes in patients not
treated with ACE inhibitors or angiotensin II receptor
blockers.
Baseline clinical and laboratory investigations All patients
had blood samples and phenotypic characteristics collected
as part of the EURAGEDIC project [23]. BP was measured
twice in the resting state. Plasma lipid levels were
determined from venous samples by standard methods.
HbA1c was determined by standard HPLC techniques with
normal values in the range 4.1–6.4%. Urinary AER
(UAER) was measured in 24 h urine collections by an
enzyme immunoassay [24]. Serum creatinine concentration
was determined by a modification of Jaffe’s method. GFR
was measured annually in patients with diabetic nephrop-
athy after a single injection of 3.7 MBq 51Cr-labelled
EDTA by determination of radioactivity in venous blood
samples taken 180, 200, 220 and 240 min after injection
[25]. Linear regression analysis of serial GFR determina-
tions in each individual was used to estimate the rate of
decline in kidney function with time (ΔGFR). ESRD was
defined as kidney transplantation or dialysis. Diabetic
retinopathy was assessed by fundus photography after
pupillary dilatation and graded nil, simplex and prolifera-
tive retinopathy, respectively. Based on standardised ques-
tionnaires, current smokers of one or more cigarettes, cigars
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or pipes per day were classified as smokers and all others as
non-smokers. Cardiovascular disease was considered pres-
ent at baseline in patients with a history of admission for
stroke or myocardial infarction. Plasma osteoprotegerin was
measured by a sandwich ELISA using commercially
available antibodies (R&D Systems, Minneapolis, MN,
USA), as previously described [13]. Briefly, mouse anti-
human osteoprotegerin (R&D Systems) was used as capture
antibody and a biotinylated goat anti-human osteoprote-
gerin (R&D Systems) for detection. Recombinant human
osteoprotegerin was used for calibration and the analytical
range of the assay was 62.5–4,000 ng/ml. Plasma samples
were diluted 1/3 and measured in duplicate. The intra-assay
CV, as judged from duplicate measurements, was 3%. The
interassay variation was 8% (n=18 control samples) in the
present series of analysis. The samples were analysed in
random order. Repeated freeze–thawing did not have any
effect on results.
Follow-up In a prospective observational study design, the
patients were followed until an endpoint was reached: the
last visit to the Steno Diabetes Center or 1 September 2006.
The primary endpoints were all-cause mortality, cardiovas-
cular mortality and major cardiovascular events; secondary
endpoints were progression of nephropathy (ΔGFR and
ESRD).
All patients were traced through the national register
during autumn 2006. If a patient died before 1 September
2006, the date of death was recorded and information on
cause of death was obtained from the death certificate. Two
observers reviewed all death certificates independently and
the primary cause of death was recorded. Additional
available information from necropsy reports was included.
All deaths were classified as cardiovascular deaths unless
an unequivocal non-cardiovascular cause was established
[26]. Information about date of ESRD and non-fatal
cardiovascular events were obtained from patient records
or discharge letters from other hospitals. Major cardiovas-
cular events were diagnosed as stroke, myocardial infarc-
tion, coronary artery bypass graft and/or percutaneous
coronary intervention.
The study was performed in accordance with the Declara-
tion of Helsinki, the local ethics committee approved the
study and all patients gave their informed consent.
Statistical analysis Normally distributed variables are given
as mean±SD, whereas non-normally distributed variables
were log-transformed before analysis and are given as
median (range). Comparisons between groups were per-
formed by unpaired Student’s t test or ANOVA. The χ2 test
was used to compare non-continuous variables. A two-
tailed p value of ≤0.05 or less was considered statistically
significant.
Log osteoprotegerin concentration was normally distrib-
uted and patients were divided into quartiles on the basis of
the distribution of osteoprotegerin values. All time-to-
endpoint variables were analysed using a log-rank test and
displayed on Kaplan–Meier plots as 1 minus cumulative
survival. Cox regression models were used to estimate the
unadjusted and adjusted hazard ratios with 95% CI. When
analysing primary endpoints, we adjusted for the following
covariates at baseline: sex, age, smoking, systolic BP,
HbA1c, GFR, serum cholesterol, UAER, antihypertensive
treatment and history of cardiovascular events. In an
additional analysis we also adjusted for C-reactive protein
and N-terminal prohormone brain natriuretic peptide (NT-
proBNP). When analysing data on ESRD and ΔGFR, we
performed adjustment for sex, age and well-known pro-
gression promoters including systolic BP, HbA1c, serum-
cholesterol, GFR, UAER and antihypertensive treatment.
All covariates were entered in the Cox regression model
when adjustments were performed. Areas under the receiver
operating characteristic curves and their 95% CIs were
estimated.
All calculations were performed using a commercially
available program (SPSS for Windows, version 14.0; SPSS,
Chicago, IL, USA).
Results
Baseline characteristics The study was a prospective
observational follow-up study with a median follow-up
time until endpoint or last visit of 11.3 (0.0–12.9) years.
The study population included two groups: 397 patients
with type 1 diabetes and diabetic nephropathy and 176
controls with type 1 diabetes for more than 15 years and
persistent normoalbuminuria. Baseline clinical and labora-
tory characteristics of the 573 patients are shown in Table 1.
Patients with diabetic nephropathy received more insulin
and antihypertensive medication, had higher BMI, HbA1c,
BP, serum creatinine, total cholesterol, serum triacylgly-
cerol and osteoprotegerin levels but lower concentrations of
HDL than patients with type 1 diabetes and normoalbumi-
nuria (p<0.05). On average, GFR was well preserved in
patients with diabetic nephropathy.
Follow-up data Osteoprotegerin was measured in 176
patients with normoalbuminuria (2.6 (1.4–8.2) μg/ml).
During the follow-up period, six patients (7%) with
osteoprotegerin levels below the median and 14 patients
(16%) with osteoprotegerin levels above the median died.
The log rank test demonstrated a significant difference
between the groups (p=0.006). Furthermore, when apply-
ing Cox regression analysis high levels of osteoprotegerin
revealed a fourfold increased risk for all-cause mortality
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in relation to low levels (hazard ratio [HR] 4.10, 95% CI
1.37–12.28; p=0.012). However, this relationship disap-
peared after adjusting for baseline variables. Because of the
low number of events in the normoalbuminuric group,
further analyses are restricted to patients with diabetic
nephropathy.
The 397 patients with diabetic nephropathy were divided
into quartiles according to osteoprotegerin levels (≤2.40,
2.41–2.97, 2.98–3.83, ≥3.84 μg/ml). Ten patients with
osteoprotegerin levels in the first quartile (10%), 21 patients
in the second quartile (21%), 35 patients in the third
quartile (35%) and 60 patients in the fourth quartile (61%)
died during follow-up. Figure 1 shows the Kaplan–Meier
curve for overall mortality in patients with diabetic
nephropathy (p<0.001). An eightfold increased risk of
all-cause mortality was found for high (fourth quartile) vs
low (first quartile) levels of osteoprotegerin (HR 8.26
[4.23–16.15], p<0.001). High osteoprotegerin remained an
independent predictor of all-cause mortality in the Cox
regression model (covariate-adjusted HR 3.00 [1.24–7.27],
p=0.015) (Table 2). We then examined whether high levels
of osteoprotegerin were associated with an increased risk of
cardiovascular mortality. During follow-up, six patients
with osteoprotegerin levels in the first quartile (6%), eight
patients in the second quartile (8%), 28 patients in the third
quartile (28%) and 39 patients in the fourth quartile (39%)
died of reasons related to cardiovascular disease. Figure 2
shows the Kaplan–Meier curve for cardiovascular mortality
(p<0.001). High levels of osteoprotegerin predicted an
increased risk of cardiovascular mortality (HR 8.76 [3.71–
20.71], p<0.001; covariate-adjusted HR 4.88, [1.57–15.14],
p=0.006) (Table 2). The same trend was seen when looking
at non-fatal cardiovascular events (n=84). High levels
increased the risk of non-fatal cardiovascular events in a
univariate proportional hazards regression analysis (HR
3.04 [1.45–6.35], p=0.003). However, this association dis-
appeared when adjusting for confounding factors (covariate-
adjusted HR 1.21 [0.46–3.20], p>0.05).
Osteoprotegerin concentration was tested for a correla-
tion with the well-known cardiovascular risk factors C-
reactive protein and NT-proBNP [27]. Osteoprotegerin con-
centration correlated with NT-proBNP (r=0.56, p<0.001)
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Fig. 1 Kaplan–Meier curves for all-cause mortality in 397 type 1
diabetic patients with diabetic nephropathy (p<0.001). Dotted black
line, first quartile of osteoprotegerin concentration; light grey line,
second quartile; dark grey line, third quartile; solid black line, fourth
quartile
Table 1 Baseline clinical and
laboratory characteristics of
573 type 1 diabetic patients
followed for 11.3 (0.0–12.9)
years according to nephropathy
status
Data are n, mean±SD or
median (range)
a Some patients with previously
persistent macroalbuminuria
receiving antihypertensive
treatment had values
<300 mg/24 h at the time
of investigation
SR, simplex retinopathy; PR,
proliferative retinopathy
Characteristic Nephropathy (n=397) Normoalbuminuria (n=176) p value
Sex (men/women) 243/154 105/71 0.78
Age (years) 42.1±10.6 42.6±9.7 0.61
Duration of diabetes (years) 28.3±8.9 27.6±8.3 0.37
BMI (kg/m2) 24.29±3.4 23.7±2.5 0.036
HbA1c (%) 9.4±1.5 8.5±1.1 <0.001
Antihypertensive treatment (%) 75.0 9.7 <0.001
Insulin dose (IU) 44.1±14.5 40.4±13.0 0.005
Systolic BP (mmHg) 145±22 132±18 <0.001
Diastolic BP (mmHg) 82±12 76±10 <0.001
UAER (mg/24 h) 609 (10–14,545)a 8 (1–30) –
Serum creatinine (mmol/l) 102 (52–684) 76 (53–116) <0.001
GFR (ml min−1 1.73 m−2) 67±28 – –
Serum cholesterol (mmol/l) 5.6±1.2 4.8±1.0 <0.001
Serum HDL-cholesterol (mmol/l) 1.5±0.7 1.6±0.5 0.001
Serum triacylglycerol (mmol/l) 1.3 (0.3–9.9) 0.8 (0.3–3.0) <0.001
Smoking (%) 46.7 42.6 0.41
Retinopathy (0/SR/PR) 6/129/262 62/95/19 <0.001
Myocardial infarction (%) 4.0 1.1 0.07
Stroke (%) 6.5 0.6 <0.001
NT-proBNP (ng/l) 89.1 (5–35 000) 27.8 (5–453) <0.001
C-reactive protein (mg/l) 1.2 (0.1–52) 0.9 (0.1–47) 0.002
Osteoprotegerin (μg/ml) 3.0 (1.4–11.4) 2.6 (1.4–8.2) <0.001
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but not with C-reactive protein (r=0.02, p=0.73). The
predictive value of osteoprotegerin remained unchanged if
these markers were included in the analysis of cardio-
vascular mortality. The covariate-adjusted HR was 4.90
when comparing the fourth and first osteoprotegerin
quartiles (1.55–15.49, p=0.007). Similar trends were seen
for other endpoints, but nevertheless the predictive value of
osteoprotegerin was moderately reduced. In addition,
evaluating osteoprotegerin as a continuous variable intro-
duced only minor changes in the statistical output.
Furthermore, when performing the same analyses for all
patients (n=573) adjusting for the presence or absence of
nephropathy, similar results were seen.
The overall prognostic value of osteoprotegerin for
overall mortality was evaluated as the mean area under
the receiver operating curve. For osteoprotegerin the AUC
was 0.75 (0.70–0.81). Furthermore, the AUCs for a risk
score for the model containing other variables (sex, age,
smoking, systolic BP, HbA1c, serum cholesterol, GFR,
UAER, antihypertensive treatment and history of cardio-
vascular events) with and without osteoprotegerin were
0.83 (0.79–0.88) and 0.82 (0.78–0.87), respectively.
Progression of nephropathy In the group of patients with
diabetic nephropathy, progression to dialysis or transplan-
tation was seen in six patients in the first quartile (6%), nine
patients in the second quartile (9%), 21 patients in the third
quartile (21%) and 34 patients in the fourth quartile (35%)
(Fig. 3) (p<0.001). Cox regression analysis revealed a
ninefold increased risk of ESRD in patients with high
osteoprotegerin levels in relation to low levels (HR 9.28
[3.89–22.14], p<0.001). This relationship persisted after
adjusting for confounding factors (covariate-adjusted HR
4.32 [1.45–12.87], p=0.009) (Table 2).
In addition, the rate of decline in kidney function was
explored using annually measured GFR (n=386 patients).
The mean annual rate of decline in GFR differed signifi-
cantly according to osteoprotegerin levels: first quartile 3.7
(4.2) ml min−1 1.73 m−2; second quartile 4.0 (3.1) ml min−1
1.73 m−2; third quartile 4.8 (4.3) ml min−1 1.73 m−2; fourth
quartile 4.9 (4.4) ml min−1 1.73 m−2; p=0.015. This effect
persisted after correction for well-known progression pro-
moters (p=0.017).
Discussion
This prospective observational follow-up study revealed that
plasma osteoprotegerin concentration is a novel independent
risk marker for all-cause and cardiovascular mortality in type
Pro/X genotype (n = 400)
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Fig. 3 Kaplan–Meier curves of ESRD in 397 type 1 diabetic patients
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Fig. 2 Kaplan–Meier curves for fatal cardiovascular (CVD) events in
397 type 1 diabetic patients with diabetic nephropathy (p<0.001).
Dotted black line, first quartile of osteoprotegerin concentration; light
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Table 2 Hazard ratio of long-term cumulative mortality, cardiovas-
cular mortality and ESRD after adjustment for confounding factors
Parameter Hazard ratio 95% CI p value
All-cause mortalitya
Second vs first quartile 1.83 0.79–4.22 0.157
Third vs first quartile 2.15 0.93–4.98 0.074
Fourth vs first quartile 3.00 1.24–7.27 0.015
Cardiovascular mortalitya
Second vs first quartile 1.32 0.43–4.09 0.631
Third vs first quartile 3.81 1.32–10.95 0.013
Fourth vs first quartile 4.88 1.57–15.14 0.006
ESRDb
Second vs first quartile 2.14 0.66–6.85 0.202
Third vs first quartile 3.94 1.36–11.38 0.011
Fourth vs first quartile 4.32 1.45–12.87 0.009
aPrimary endpoints are adjusted for the following confounding
factors: sex, age, smoking, BP, HbA1c, GFR, serum cholesterol,
UAER, antihypertensive treatment and a history of cardiovascular
events at baseline
bThe secondary endpoint is adjusted for the following confounding
factors: sex, age, systolic BP, HbA1c, serum cholesterol, GFR, UAER
and antihypertensive treatment
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1 diabetic patients with overt nephropathy. Moreover, we
found that the plasma osteoprotegerin concentration predicts
deterioration of kidney function. These predictive capacities
persisted after adjustment for conventional cardiovascular
and renal risk factors, including GFR.
Osteoprotegerin in the arterial wall Osteoprotegerin is a
120 kDa secretory glycoprotein belonging to the TNF
receptor superfamily. It was first discovered in bone [1] but
is also present in large amounts in the arterial wall [4].
Osteoprotegerin may be involved in the development of
vascular calcifications, since immunohistochemical studies
have shown co-localisation of osteoprotegerin and areas of
calcification in media and atherosclerotic plaques [28].
Experimental studies have shown associations between
vascular calcification in vitro and osteoprotegerin produc-
tion [9]. In addition, osteoprotegerin has also been
suggested to be a survival factor for endothelial cells [29].
Nevertheless, osteoprotegerin knockout mice develop vas-
cular calcifications [30].
Osteoprotegerin and diabetes As previously shown, osteo-
protegerin accumulates in aorta from patients with type 1
and type 2 diabetes [4]. This accumulation is seen in the
tunica media from areas of the tissue with and without
atherosclerotic plaques. The accumulation of osteoprote-
gerin throughout the deeper layers of the vessel wall may
reflect generalised changes in the arterial system in
diabetes, as part of diffuse arterial changes such as
alterations in glycoproteins [31], collagens [32] and
glycosaminoglycans [33]. In addition, osteoprotegerin may
be related to the development of medial calcification, which
is frequently present in patients with diabetes [34, 35]. Two
recent experimental studies have confirmed the finding of
increased expression of the gene encoding osteoprotegerin
and production of the protein in arteries from animals with
experimental diabetes [10, 11]. At a first glance, it may
seem contradictory that osteoprotegerin—a putative bene-
ficial calcification inhibitor—accumulates in the arterial
system in diabetes and that a high concentration of plasma
osteoprotegerin is a cardiovascular risk marker. However,
osteoprotegerin accumulation may be part of an osteogenic
differentiation of vascular cells, as a compensatory response
against calcification [36]. A series of other factors related to
vascular calcification, such as vitamin D, BMP2, fetuin,
matrix γ-carboxyglutamic acid (Gla) protein and osteopontin
may also be relevant to this context. However, there is no
information about these factors in relation to diabetic
macrovascular disease. Alternatively, alterations in arterial
osteoprotegerin amounts in diabetes may reflect direct effects
of hormonal and inflammatory factors, since osteoprotegerin
production can be influenced by both TNF-α and insulin in
vascular smooth muscle cells in vitro [4].
A recent study has observed that osteoprotegerin is
strongly upregulated at the RNA level in kidney samples
from patients with diabetes [37]. This is interesting in
relation to our observation that osteoprotegerin concentra-
tion predicts ESRD.
Plasma osteoprotegerin and cardiovascular risk Plasma
osteoprotegerin concentration correlates to both diabetes and
cardiovascular disease in cross-sectional studies. This was
first shown by Browner et al. [12], who reported that although
no associations were seen between the bone parameters and
plasma osteoprotegerin levels, individuals with diabetes as
well as persons with cardiovascular disease had increased
values. Since then, these findings have been confirmed in
both type 1 [38, 39] and type 2 diabetes [13, 40]. Moreover,
we recently found that plasma osteoprotegerin is increased in
subgroups of type 1 diabetic patients with nephropathy and in
subgroups with signs of cardiovascular disease [18]. In line
with the suggestion that osteoprotegerin is an inhibitor of
vascular calcification, it is interesting that plasma osteopro-
tegerin is associated with arterial calcification in humans, as
estimated by different modern imaging techniques [16, 41].
Only a few prospective studies on plasma osteoprotegerin as
a putative predictor of cardiovascular events have been
published. Anand et al. found in a study of 510 type 2
diabetic individuals that high levels of plasma osteoprote-
gerin predicted cardiovascular events over a relative short
observation period of approximately 18 months [19].
Moreover, in post-kidney-transplant non-diabetic patients at
high cardiovascular risk, serum osteoprotegerin was recently
shown to predict long-term patient survival and cardiovascu-
lar mortality very well [20]. Our finding of a strong
predictive effect of plasma osteoprotegerin in type 1 diabetic
individuals with nephropathy supports the finding that the
circulating osteoprotegerin level reflects arterial osteoprote-
gerin accumulation, as part of a generalised arteriopathy
related to calcifications. Alternatively, the predictive value of
osteoprotegerin may relate to a possible association to heart
failure, which a recent study indicated [42]. Although data on
heart failure are not available in the present study, our finding
of an association between osteoprotegerin and NT-proBNP
supports this notion.
Conclusion Our data show that plasma osteoprotegerin is a
strong and independent predictor of all-cause and cardio-
vascular mortality as well as for deterioration of kidney
function in patients with nephropathy. One explanation may
be that osteoprotegerin accumulates in the vascular wall in
diabetes as part of the macroangiopathy. High plasma levels
may thus reflect the degree of macrovascular disease and
consequently predict cardiovascular disease. Our present
findings point to the clinical use of plasma osteoprotegerin
for future risk stratification of these patients.
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